Citius Oncology (CTOR) Long-Term Deferred Tax (2023 - 2026)

Citius Oncology (CTOR) has 3 years of Long-Term Deferred Tax data on file, last reported at $169252.0 in Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $169252.0 in Q1 2026; TTM through Mar 2026 was $169252.0, a N/A change from a year earlier, with the FY2024 full-year figure at $7.5 million, up 62.07% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $169252.0, down from $7.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for CTOR reached as high as $7.5 million in Q3 2024 and fell as low as $169252.0 in Q1 2026.
• Historically, Long-Term Deferred Tax has averaged $4.1 million across 3 years, with a median of $4.6 million in 2023.
• On a YoY basis, Long-Term Deferred Tax climbed as much as 62.07% in 2024 and fell as far as 62.07% in 2024.
• Year by year, Long-Term Deferred Tax stood at $4.6 million in 2023, then jumped by 62.07% to $7.5 million in 2024, then sank by 97.75% to $169252.0 in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $169252.0 in Q1 2026, $7.5 million in Q3 2024, and $4.6 million in Q3 2023.